NEW YORK – Biodesix said Wednesday that it has formed a partnership with Spesana to automate the use of molecular diagnostics in clinical workflows for lung cancer. The firms expressed hope that their partnership will accelerate the adoption of precision medicine and enrollment in clinical trials.
Spesana, a startup based in Memphis, Tennessee, has developed visualization-based clinical decision support software that integrates data from electronic medical records, laboratory information systems, and molecular diagnostics to help medical practitioners make sense of MDx tests and the massive amounts of data that accompany them. The company's technology also automates referral management, tumor boards, and clinical trial management.
Through the partnership, Spesana will integrate electronic ordering of Biodesix tests, including the Nodify Lung nodule risk assessment and IQlung tests. Spesana will also provide clinical education and a virtual engagement platform.
"The Spesana platform enables easy and open communication and data sharing for all physicians within a health system to align on their patient's care," Scott Hutton, CEO of Boulder, Colorado-based Biodesix, said in a statement.
"Physicians believe in precision medicine, yet struggle with the current logistics and workflow to order, track, and receive molecular diagnostic test results to make evidence-based decisions for their patients," said Spesana CEO Carla Balch. "Together [with Biodesix], our goal is to improve the user experience with an elegant data-driven workflow and highly sensitive molecular diagnostics to improve patients' outcomes and significantly improve upon the unnecessarily complicated processes that exist now."